Cargando…

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI

BACKGROUND: Non-invasive imaging biomarkers underpin the development of molecularly targeted anti-cancer drugs. This study evaluates tumour apparent diffusion coefficient (ADC), measured by diffusion-weighted magnetic resonance imaging (DW-MRI), as a biomarker of response to the MEK1/2 inhibitor sel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beloueche-Babari, M, Jamin, Y, Arunan, V, Walker-Samuel, S, Revill, M, Smith, P D, Halliday, J, Waterton, J C, Barjat, H, Workman, P, Leach, M O, Robinson, S P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776979/ https://www.ncbi.nlm.nih.gov/pubmed/23942066 http://dx.doi.org/10.1038/bjc.2013.456

Ejemplares similares

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors
por: Desar, Ingrid M. E., et al.
Publicado: (2012)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
por: Board, R E, et al.
Publicado: (2009)

Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
por: Carvajal, Richard D., et al.
Publicado: (2015)

Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
por: Gao, Jin-Hang, et al.
Publicado: (2015)

Author Correction: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer
por: Gao, Jin-Hang, et al.
Publicado: (2022)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
por: Leijen, Suzanne, et al.
Publicado: (2011)

Resistance to Selumetinib (AZD6244) in Colorectal Cancer Cell Lines is Mediated by p70S6K and RPS6 Activation()
por: Grasso, Silvina, et al.
Publicado: (2014)

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours
por: Beloueche-Babari, M, et al.
Publicado: (2015)

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2018)

Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
por: Song, Hao, et al.
Publicado: (2022)

Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition
por: Beloueche-Babari, Mounia, et al.
Publicado: (2010)

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells
por: Troiani, T, et al.
Publicado: (2012)

Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration
por: Beloueche-Babari, Mounia, et al.
Publicado: (2020)

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models
por: Qu, Yiqing, et al.
Publicado: (2014)

False-negative MRI biomarkers of tumour response to targeted cancer therapeutics
por: Boult, J K R, et al.
Publicado: (2012)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging
por: Shah, Anant, et al.
Publicado: (2017)

Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer
por: Azzariti, A, et al.
Publicado: (2011)

Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy
por: Beloueche-Babari, M, et al.
Publicado: (2010)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
por: Haslett, K., et al.
Publicado: (2021)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer
por: Appels, N M G M, et al.
Publicado: (2008)

Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation
por: Zhang, Qin, et al.
Publicado: (2018)

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
por: Nakai, Chikako, et al.
Publicado: (2023)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation
por: Schweyer, S, et al.
Publicado: (2004)

Profile of selumetinib and its potential in the treatment of melanoma
por: Kim, Dae Won, et al.
Publicado: (2014)

AZD4625 is a Potent and Selective Inhibitor of KRAS(G12C)
por: Chakraborty, Atanu, et al.
Publicado: (2022)

The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo
por: Zou, Yun, et al.
Publicado: (2017)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib
por: Novo, Sonia M., et al.
Publicado: (2017)

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
por: Morgillo, F, et al.
Publicado: (2011)

Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study
por: MacRae, Calum A., et al.
Publicado: (2022)

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells
por: Kim, Ki Hyung, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_3erpc6uehsfk6mk1k569oe8te1